Article Text

Download PDFPDF

2022-RA-791-ESGO Primary debulking surgery versus neoadjuvant chemotherapy and interval debulking surgery for advanced epithelial ovarian cancer
  1. Lorena Gonzalez Gea,
  2. Ingrid Perez Martinez,
  3. Emilia Ferrer Civeira,
  4. Daniel Martinez Campo,
  5. Paloma Garbayo Sesma,
  6. Belen Santacruz and
  7. Maria Dolores Muñoz Gonzalez
  1. Torrejon University Hospital, Madrid, Spain


Introduction/Background To compare the long-term survival outcomes for patients with stage IIIC or IV epithelial ovarian cancer who was treated with neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS) or primary debulking surgery (PDS) at a single community center.

Methodology We performed a retrospective review of 39 patients with stage IIIC or IV high-grade ovarian cancer who received NAC or PDS between December 2011 to November 2019 treated at Torrejon University Hospital in Madrid. Clinicopathologic and treatment data were analysed for factors associated with response to NAC, outcomes at IDS, and their impact on progression-free survival (PFS) and overall survival (OS).

Results A total of 28 patients (71.80%) received NAC and 11 patients (28,20%) underwent PDS. Women who received NAC have the same probability for no residual tumour surgery than those with PDS (76.92% vs. 70%; NS). Difference was observed in PFS and OS between NAC group and PDS group (PFS: 15,32 vs. 23,56 months p = 0.033; OS: 14, 81 vs. 21,56 months, p = 0.078). No statistically significance differences were seen concerning age (60 years vs 53 years), IMC (25.7 vs. 27.4), operating time (282.8 minutes vs. 319.5 minutes) and hospital stay (5.9 days vs.7.2 days) between NAC and PDS group. Hemoglobin operative balance was lower in NAC group than PDS group (2.08 mg/dL vs. 3.25 mg/dL; p= 0.022). CA125 levels at cancer diagnosis were lower at NAC group than at PDS group (median: 2243.2 vs. 246.9 U/mL;p=0,048). With an overall median follow-up of 54 months (3–120), 23 (69.7%) disease progressions/recurrences and 20 deaths(58.8%) occurred.

Conclusion Among women with advanced ovarian cancer, those who underwent primary cytoreductive surgery had better survival than those who received neoadjuvant chemotherapy. Neoadjuvant chemotherapy should be reserved for those in whom optimal primary cytoreductive surgery is not feasible.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.